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Purpose: Choroidal osteomas are benign intraocular tumors that classically present in females. Despite
their benign nature, signiﬁcant visual acuity loss can occur due to retinal pigment epithelium degen-
eration. We report an unusual case of bilateral choroidal osteoma in a young boy.
Observation: A 16 year old boy presented to the Aga Khan University Hospital with a history of painless,
bilateral deteriorating vision over past few months. Examination showed best corrected visual acuity as
20/200 in the right eye and 20/400 in the left eye. Funduscopy revealed a well-deﬁned lesion in the
juxtafoveal region of both eyes. A diagnosis of (bilateral) choroidal osteoma was subsequently made on
the basis of optical coherence tomography, fundus ﬂuorescein angiography, Indocyanine green and B-
scan ultrasonography. The presence of choroidal neovascularization with sub retinal ﬂuid was also
established on OCT. The patient was treated with three intravitreal Ranizumab injections. At the follow
up visit, vision had improved to 20/50 in the right eye and 20/200 in the left. Sub retinal ﬂuid had also
resolved.
Conclusions: and importance: Intravitreal Ranizumab may be an effective alternative in the management
of choroidal neovascularization secondary to choroidal osteoma.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Choroidal osteomas are rare, benign intraocular tumors, ﬁrst
described in 1979 by Gass et al..1 They are characterised by the
presence of mature, cancellous bone within the choroid and are
classically found as unilateral lesions in females in their second or
third decade of life. On fundus examination, choroidal osteomas
appear as slightly and irregularly elevated, orange-yellow plaques
deep to the retina in the juxta papillary or macular region with
well-deﬁned geographic borders.1e3The pathogenesis and etiology
of the tumor however, is still not well understood.
Despite being benign tumors, choroidal osteomas can often
cause severe loss of visual acuity secondary to gradual atrophy of
the overlying retina pigment epithelium (RPE) or by accumulation
of either sub retinal ﬂuid or sub retinal hemorrhagewith or without
choroidal neovascularization (CNV).4 Treatment options have
included laser photocoagulation, excision of CNV, photodynamicimabad, Karachi, Pakistan.
ar).
Inc. This is an open access article utherapy (PDT) and trans pupillary thermal therapy (TTT) and more
recently, the use of intravitreal anti-vascular endothelial growth
factor (VEGF).
We evaluated the role of anti-VEGF therapy in the treatment of
CNV in choroidal osteomas after their use in some case reports.2. Case report
A healthy 16 years old boy presented to the ophthalmology
consulting clinics, Aga Khan University Hospital with bilateral
deteriorating vision over the past fewmonths. Best corrected visual
acuity (BCVA) was 20/200 in the right eye and 20/400 in the left
eye. Past ocular history was signiﬁcant for receiving 7 bevacizumab
injections (Avastin; Genentech, Inc., South San Francisco, CA) for a
choroidal hemangioma. Rest of the history was unremarkable. On
clinical examination, an orange-yellow plaque was noted in the
juxtafoveal region of both eyes with associated calciﬁcation (Fig. 1A
and B). The osteoma gave the characteristic appearance of a
pseudo-optic nerve on B-scan ultrasonography, appearing as a
slightly elevated, highly reﬂective choroidal mass (Fig. 2C and D).
Fundus ﬂuorescein angiography (FFA) showed early, patchy hypernder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. (A) A yellowish-choroidal lesion is noted in the left eye with well-deﬁned borders. (B) A similar lesion can also be appreciated in the right eye. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. (A) and (B) Optical coherence tomography scan of the right eye and left eye, respectively. The choroidal neovascular membrane can be visualized on scans of both the eyes
highlighted using the yellow arrow. The blue arrow demonstrates presence of sub retinal ﬂuid. 2 (C) and 2(D) B-scan ultrasonography appears as slightly elevated, highly reﬂective
choroidal mass with acoustic shadowing bilaterally. The white arrow highlights the characteristic pseudo-optic nerve ﬁnding associated with choroidal osteomas. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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areas of calciﬁcation (Fig. 3A and B). On optical coherence tomog-
raphy (OCT), an irregular hyper reﬂective area was observed in the
choroid with sub retinal ﬂuid overlying the osteoma (Fig. 2A and B).
Indocyanine green showed areas of hypoﬂuorescence in the early
phase as well as hyperﬂuorescent in late frames (Fig. 3C and D). A
diagnosis of choroidal osteomas was made for both eyes with
associated choroidal neovascularization (CNV) and sub retinal ﬂuid.
A decision was made to treat the patient with intravitreal ranibi-
zumab ([0.5 mg] Lucentis; Genentech, Inc., South San Francisco,
CA). The potential risks and beneﬁts of the intravitreal injection of
ranibizumab were explained to the patient and written consent
was obtained. A total of three injections were administered, each
separated by a month’s duration. At the 2-week follow up, visualacuity had improved to 20/50 in the right eye and 20/200 in the left.
The sub retinal ﬂuid had also resolved.3. Discussion
Choroidal osteomas are rare, ossifying tumors that classically
occur as unilateral lesions affecting middle-aged women.2 In two of
the largest long-term studies involving choroidal osteomas, anal-
ysis of 36 and 74 patients over a period of 10 and 26 years
respectively, revealed bilateral lesions in only 25% of the cases with
67%e89% affected being female.2,3 Our case is therefore unique as it
presented as a bilateral lesion in a young male, which is an un-
common ﬁnding.5
Fig. 3. (A) and (B) Fundus Fluorescein Angiography with early patchy hyperﬂuorescence and late diffuse staining in areas of calciﬁcation. 3(C) and 3(D) demonstrate hypo ﬂuo-
rescence of mass on Indocyanine green with diffuse hyper ﬂuorescence in late frames.
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attributed to decalciﬁcation occurring from disruption of the tu-
mor. Subsequently, the insult may result in damage to the RPE, CNV,
and appearance of sub retinal ﬂuid and/or hemorrhages.
Management of CNV associated with choroidal osteomas is a
challenging issue. Various treatments have included laser photo-
coagulation, surgical removal of CNV and TTT but have achieved
limited success. Laser photocoagulation of CNV associated with
choroidal osteoma has largely been unsuccessful. In a long-term
study conducted by Aylward et al. successful treatment was ach-
ieved in only 25% of the eyes. It is hypothesized that, owing to
depigmentation of the RPE, there is decreased absorption of laser
energy and hence, reduced treatment efﬁcacy.3 Surgical removal of
CNV and TTT have also been tried but with poor visual out-
comes.6e8 More recent treatments have included photodynamic
therapy (PDT) and intravitreal bevacizumab (Avastin) or ranibizu-
mab (Lucentis).
Anti-VEGF has successfully been used in the treatment of CNV
associated with different ocular diseases including age-related
macular degeneration (ARMD) and diabetic retinopathy. Various
studies have also reported efﬁcacy of anti-VEFG in inducing
remission of CNV secondary to choroidal osteomas4,7,9e11 Use of
PDT has also shown to have multiple beneﬁts including improved
visual acuity and metamorphopsia as well as a reduction in the size
of the CNV. However, relative to anti-VEGF, PDT is associated with
poor visual outcome and the possible need for multiple re-treatments.10 Focal decalciﬁcation of the tumor may also occur
following treatment which may again be visually detrimental.
After assessing all of the possible treatment options, we suc-
cessfully treated our patient with intravitreal ranibizumab. Rani-
bizumab reduces permeability of choroidal vessels through its
inﬂuence on VEGF levels resulting in a signiﬁcant decrease in sub
retinal ﬂuid, as well as improved visual acuity overall.
4. Conclusion
Although choroidal osteomas remain a rare ocular pathology,
signiﬁcant progress has been made in treating choroidal osteoma
associated CNV, a signiﬁcant cause of visual impairment in these
patients. Anti-VEGF, the newest therapeutic modality has success-
fully shown to resolve CNV and/or associated sub retinal ﬂuid and
hemorrhages. Furthermore, it is associated with few complications
and a good visual outcome.
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